Breaking out of research silos and collaborating more openly will be a big step in driving personalized medicine forward, said Dr. Andrew Futreal, a professor of genomic medicine at MD Anderson.
While the world’s biopharma players are still working to solve the problem of R&D productivity, they’re hardly being stingy in the process. R&D spending across the industry leapt 14% last year, according to EY, a sharp rebound reflecting renewed optimism among drug developers and their investors.
U.S. Sen. Dick Durbin received a standing ovation Monday morning in front of Illinois University School of Medicine faculty members after the Springfield Democrat explained his proposed $150 billion initiative to boost federal spending on scientific research.
Sorry for the lack of posts recently. I have been working on an exciting project that I will be announcing/launching soon. Until then, enjoy…
Moving from drug discovery to drug development requires a particular skillset usually not yet honed by start-ups. This phase of the development process is highly regulated and critical. Let Dr. Colin Minchom take you through the aspects of the Chemistry, Manufacturing and Control (CMC) portion of the drug development process.
Watch this video to learn about the pharmaceutical product development which includes objectives of formulation, cost-effective strategies to reach key milestones and more.
How can big data can revolutionize pharmaceutical R&D? Is this the latest fad in building a better R&D model?
McKinsey director Sam Marwaha discusses big data and advanced analytics implementation, he reviews eight technology-enabled measures that can improve the way R&D functions gather, analyze, and apply data—to help replenish stagnant pipelines and lift success rates and the potential benefits to integrating analytics across different health-care disciplines.